Tinsley Harrison Internal Medicine Residency Program, The University of Alabama at Birmingham (UAB), Birmingham, AL, USA.
Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham (UAB) and Birmingham VA Medical Center, Birmingham, AL, USA.
Curr Opin Pharmacol. 2022 Aug;65:102241. doi: 10.1016/j.coph.2022.102241. Epub 2022 May 21.
Gout is a common and potentially debilitating disease characterized by a painful inflammatory arthritis ("gout flare"), caused by the deposition of monosodium urate crystals in joints and surrounding tissues. Gout is frequently comorbid with other chronic conditions such as chronic kidney disease (CKD) and diabetes mellitus, which can make treatment complex, as traditional mainstays (such as allopurinol, colchicine, and corticosteroids) may not be preferred or could have adverse events in such patients. Understanding the pathophysiology of hyperuricemia, gout, and crystalline-driven inflammation is key for drug development and research. Consequently, new agents and new protocols with existing agents are being proposed for safe and efficacious treatment in patients with a variety of comorbid conditions. This review will discuss such strategies that may be used in the future for gout treatment.
痛风是一种常见且可能致残的疾病，其特征为单钠尿酸盐晶体在关节和周围组织沉积引起的疼痛性炎症性关节炎（“痛风发作”）。痛风常与其他慢性疾病同时存在，如慢性肾脏病（CKD）和糖尿病，这使得治疗变得复杂，因为传统的主要治疗方法（如别嘌醇、秋水仙碱和皮质类固醇）可能不受青睐，或者在这些患者中可能会产生不良反应。了解高尿酸血症、痛风和晶体驱动炎症的病理生理学对于药物开发和研究至关重要。因此，正在为患有各种合并症的患者提出新的药物和现有药物的新方案以进行安全有效的治疗。本文将讨论未来可能用于痛风治疗的此类策略。
